Results 281 to 290 of about 77,372 (337)
Some of the next articles are maybe not open access.
Trends in Endocrinology & Metabolism, 1998
Adrenal Glands, Vascular System and Hypertension Edited by G.P. Vinson and D.C. Anderson. Bristol, UK, Society for Endocrinology, $95.00/ pound50.00 (312 pages), ISBN 1-898099-07-3.
openaire +2 more sources
Adrenal Glands, Vascular System and Hypertension Edited by G.P. Vinson and D.C. Anderson. Bristol, UK, Society for Endocrinology, $95.00/ pound50.00 (312 pages), ISBN 1-898099-07-3.
openaire +2 more sources
Steroids, 1996
Pseudohypoaldosteronism was first described in 1958 by Cheek and Perry, who reported an infant with severe salt wasting in the absence of any renal or adrenal defect. Since then several reports have described patients affected by symptoms consistent with resistance to mineralocorticoid action.
openaire +2 more sources
Pseudohypoaldosteronism was first described in 1958 by Cheek and Perry, who reported an infant with severe salt wasting in the absence of any renal or adrenal defect. Since then several reports have described patients affected by symptoms consistent with resistance to mineralocorticoid action.
openaire +2 more sources
Apparent mineralocorticoid excess
The Journal of Steroid Biochemistry and Molecular Biology, 1995Apparent mineralocorticoid excess is a syndrome reflecting the absent or impaired activity of the enzyme 11β-hydroxysteroid dehydrogenase Type 2. It may be mild when the mutant enzyme retains some activity, or severe when activity is absolutely or essentially absent.
openaire +3 more sources
Apparent mineralocorticoid excess
Trends in Endocrinology & Metabolism, 2001Apparent mineralocorticoid excess (AME) is a potentially fatal genetic disorder causing severe juvenile hypertension, pre- and postnatal growth failure, hypokalemia and low to undetectable levels of renin and aldosterone. It is caused by autosomal recessive mutations in the HSD11B2 gene, which result in a deficiency of 11 beta-hydroxysteroid ...
R C, Wilson, S, Nimkarn, M I, New
openaire +2 more sources
Mineralocorticoid receptor antagonists
Current Hypertension Reports, 2007With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan +1 more
openaire +3 more sources
Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta +2 more
openaire +2 more sources
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta +2 more
openaire +2 more sources
Monogenic mineralocorticoid hypertension
Best Practice & Research Clinical Endocrinology & Metabolism, 2006Monogenic mutations leading to excessive activation of the mineralocorticoid pathway result, almost always, in suppressed renin and hypertension in adult life and sometimes in hypokalaemia and alkalosis, which can be severe. In most of these syndromes, precise molecular changes in specific steroidogenic or effector genes have been identified ...
Stowasser, Michael, Gordon, Richard D.
openaire +3 more sources
Mineralocorticoid and Apparent Mineralocorticoid Syndromes of Secondary Hypertension
Advances in Chronic Kidney Disease, 2015The mineralocorticoid aldosterone is a key hormone in the regulation of plasma volume and blood pressure in man. Excessive levels of this mineralocorticoid have been shown to mediate metabolic disorders and end-organ damage more than what can be attributed to its effects on blood pressure alone.
Sivakumar Ardhanari +4 more
openaire +2 more sources
Mineralocorticoid Receptor Antagonists
2019Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
openaire +2 more sources
Adipocyte Mineralocorticoid Receptor
2019Mineralocorticoid receptor (MR) has been recently identified in adipose tissue, where its excessive activation contributes to several metabolic derangements often observed in obesity and metabolic syndrome. Recent findings support the existence of a bidirectional cross-talk between adipose tissue and adrenal glands, contributing to obesity-related ...
Infante M. +4 more
openaire +4 more sources